降低动脉粥样硬化性心血管疾病发病率相关血脂领域研究进展  

In-depth research in the field of blood lipids provides new results for further reducing the incidence of atherosclerotic cardiovascular diseases

作　　者：邓浩轩 华军益 DENG Haoxuan;HUA Junyi(Departmet of Cardiology,Zhejiang Xinhua Hospital,Hangzhou 310005,China)

机构地区：[1]浙江中医药大学附属第二医院心血管内科,杭州310005

出　　处：《心电与循环》2025年第2期136-142,共7页Journal of Electrocardiology and Circulation

摘　　要：动脉粥样硬化性心血管疾病(ASCVD)是人类主要死亡原因,发病率居高不下,血脂异常是其重要危险因素。真实世界中,由于血脂异常的发病机制复杂以及降脂治疗的达标率不尽人意,通过调脂治疗实现ASCVD发病率的降低还有很大提升空间。随着血脂领域的研究不断深入,针对不同靶标的新型降脂药物陆续问世,调脂治疗的新成果将在降低ASCVD发病率中发挥越来越重要的作用。本文从降脂新理念、调脂治疗新方法及新型降脂药物对降低ASCVD发病率研究进展作一述评。Atherosclerotic cardiovascular disease(ASCVD)is a leading cause of death in humans,with a persistently high incidence rate,and dyslipidemia is a significant risk factor.In the real world,due to the complex mechanisms of dyslipidemia and unsatisfactory achievement rates of lipid-lowering treatments,there is still considerable room for improvement in reducing the incidence of ASCVD through lipid regulation therapy.With the continuous in-depth research in the field of blood lipids,new lipid-lowering drugs targeting different markers are being introduced,and new achievements in lipid regulation treatment will play an increasingly important role in reducing the incidence of ASCVD.

关 键 词：血脂 动脉粥样硬化性心血管疾病 发病率 新型降脂药物 基因治疗 

分 类 号：R54[医药卫生—心血管疾病]